Lyell Immunopharma, Inc.
LYEL
$13.95
$0.211.53%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 27.00K | 31.00K | 36.00K | 41.00K | 60.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 27.00K | 31.00K | 36.00K | 41.00K | 60.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 27.00K | 31.00K | 36.00K | 41.00K | 60.00K |
| SG&A Expenses | 40.43M | 40.64M | 45.14M | 49.04M | 50.12M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -6.58M | -6.26M | -5.77M | -5.88M | -5.02M |
| Total Operating Expenses | 190.36M | 186.22M | 198.04M | 198.31M | 211.58M |
| Operating Income | -190.33M | -186.19M | -198.00M | -198.27M | -211.52M |
| Income Before Tax | -248.48M | -246.41M | -274.45M | -325.66M | -331.40M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -248.48 | -246.41 | -274.45 | -325.66 | -331.40 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -248.48M | -246.41M | -274.45M | -325.66M | -331.40M |
| EBIT | -190.33M | -186.19M | -198.00M | -198.27M | -211.52M |
| EBITDA | -180.81M | -175.76M | -186.47M | -184.10M | -195.24M |
| EPS Basic | -12.01 | -12.98 | -15.41 | -22.26 | -23.61 |
| Normalized Basic EPS | -5.54 | -5.98 | -7.44 | -7.64 | -8.48 |
| EPS Diluted | -12.01 | -12.98 | -15.41 | -22.26 | -23.61 |
| Normalized Diluted EPS | -5.54 | -5.98 | -7.44 | -7.64 | -8.48 |
| Average Basic Shares Outstanding | 84.02M | 75.45M | 68.33M | 61.81M | 56.36M |
| Average Diluted Shares Outstanding | 84.02M | 75.45M | 68.33M | 61.81M | 56.36M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |